Prognostic Value of Reduced SMAD4 Expression in Patients With Metastatic Colorectal Cancer Under Oxaliplatin-Containing Chemotherapy: A Translational Study of the AIO Colorectal Study Group

被引：14

作者：

Baraniskin, Alexander ^{[1
]}

Munding, Johanna ^{[2
]}

Schulmann, Karsten ^{[1
]}

Meier, Dominik ^{[1
]}

Porschen, Rainer ^{[3
]}

Arkenau, Hendrik-Tobias ^{[4
,5
]}

Graeven, Ullrich ^{[6
]}

Schmiegel, Wolff ^{[1
,2
,7
]}

Tannapfel, Andrea ^{[2
]}

Reinacher-Schick, Anke ^{[1
,7
]}

机构：

[1] Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, D-44892 Bochum, Germany

[2] Ruhr Univ Bochum, Dept Pathol, Berufsgenossenschaftliches Kliniken Bergmannsheil, D-44892 Bochum, Germany

[3] Hosp Bremen E, Clin Internal Med, Bremen, Germany

[4] Royal Marsden Hosp, Sutton, Surrey, England

[5] Inst Canc Res, Sutton, Surrey, England

[6] Kliniken Maria Hilf GmbH, Dept Hematol Oncol & Gastroenterol, Monchengladbach, Germany

[7] Ruhr Univ Bochum, Ctr Clin Studies Oncol, D-44892 Bochum, Germany

来源：

CLINICAL COLORECTAL CANCER | 2011年 / 10卷 / 01期

关键词：

5-Fluorouracil; DPC4; Immunohistochemistry; Prognostic marker; MANAGEMENT;

D O I：

10.3816/CCC.2011.n.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: SMAD4 is a polypeptide with tumor suppressor function being investigated as a prognostic biomarker in Union Internationale Contre le Cancer stages II and III in previous studies, but its role as a prognostic marker in stage IV colorectal cancer (CRC) is still undefined. We investigated the prognostic value of reduced SMAD4 expression in patients with metastatic (mCRC) under first-line oxaliplatin-containing combination chemotherapy. Patients and Methods: Tumor samples were obtained from patients who took part in a prospective randomized phase III chemotherapy trial of the Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society colorectal study group, comparing the use of capecitabine plus oxaliplatin with infusional 5-fluorouracil (5-FU) plus oxaliplatin as first-line therapy in mCRC. SMAD4 expression was determined by immunohistochemistry. Results: Tumor tissues from 230 patients were obtained. Reduced SMAD4 expression was identified in 34% of samples. Patients with reduced nuclear SMAD4 expression in tumor tissue showed a shorter progression-free survival (PFS; 7.0 months vs. 8.9 months; P = .024) and overall survival (OS; 13.9 months vs. 17.8 months; P = .044) compared with patients retaining SMAD4 expression. The effect of SMAD4 expression on PFS and OS could be demonstrated in univariate and multivariate analyses. Conclusion: Our data demonstrate the importance of reduced SMAD4 expression in patients with mCRC receiving chemotherapy with oxaliplatin and 5-FU.

引用

页码：24 / 29

页数：6

共 18 条

[1] SMAD4 as a prognostic marker in colorectal cancer [J].

Alazzouzi, H ;

Alhopuro, P ;

Salovaara, R ;

Sammalkorpi, H ;

Järvinen, H ;

Mecklin, JP ;

Hemminki, A ;

Schwartz, S ;

Aaltonen, LA ;

Arango, D .

CLINICAL CANCER RESEARCH, 2005, 11 (07) :2606-2611

[2] SMAD4 levels and response to 5-fluorouracil in colorectal cancer [J].

Alhopuro, P ;

Alazzouzi, H ;

Sammalkorpi, H ;

Dávalos, V ;

Salovaara, R ;

Hemminki, A ;

Järvinen, H ;

Mecklin, JP ;

Schwartz, S ;

Aaltonen, LA ;

Arango, D .

CLINICAL CANCER RESEARCH, 2005, 11 (17) :6311-6316

[3] Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial [J].

Bosman, Fred T. ;

Yan, Pu ;

Tejpar, Sabine ;

Fiocca, Roberto ;

Van Cutsem, Eric ;

Kennedy, Richard D. ;

Dietrich, Daniel ;

Roth, Arnaud .

CLINICAL CANCER RESEARCH, 2009, 15 (17) :5528-5533

[4] A study of lymph node ratio in stage IV colorectal cancer [J].

Derwinger, Kristoffer ;

Gustavsson, Bengt .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2008, 6 (1)

[5] Metastatic colorectal cancer:: integrating irinotecan into combination and sequential chemotherapy [J].

Douillard, JY ;

Sobrero, A ;

Carnaghi, C ;

Comella, P ;

Díaz-Rubio, E ;

Santoro, A ;

Van Cutsem, E .

ANNALS OF ONCOLOGY, 2003, 14 :7-12

[6] Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 [J].

Dy, Grace K. ;

Hobday, Timothy J. ;

Nelson, Garth ;

Windschitl, Harold E. ;

O'Connell, Michael J. ;

Alberts, Steven R. ;

Goldberg, Richard M. ;

Nikcevich, Daniel A. ;

Sargent, Daniel J. .

CLINICAL COLORECTAL CANCER, 2009, 8 (02) :88-93

[7] Estimates of the cancer incidence and mortality in Europe in 2006 [J].

Ferlay, J. ;

Autier, P. ;

Boniol, M. ;

Heanue, M. ;

Colombet, M. ;

Boyle, P. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :581-592

[8] Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer:: results of a multivariate analysis of 3825 patients [J].

Köhne, CH ;

Cunningham, D ;

Di Costanzo, F ;

Glimelius, B ;

Blijham, G ;

Aranda, E ;

Scheithauer, W ;

Rougier, P ;

Palmer, M ;

Wils, J ;

Baron, B ;

Pignatti, F ;

Schöffski, P ;

Micheel, S ;

Hecker, H .

ANNALS OF ONCOLOGY, 2002, 13 (02) :308-317

[9] A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer [J].

Leporrier, J ;

Maurel, J ;

Chiche, L ;

Bara, S ;

Segol, P ;

Launoy, G .

BRITISH JOURNAL OF SURGERY, 2006, 93 (04) :465-474

[10] Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease [J].

Maitra, A ;

Molberg, K ;

Albores-Saavedra, J ;

Lindberg, G .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (04) :1105-1111

← 1 2 →